Skip to main content
72°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics
(NQ:
RVNC
)
2.660
-0.210 (-7.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Revance Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
Revance to Participate in Upcoming Investor Conferences
March 07, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
March 02, 2023
Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify.
Via
MarketBeat
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
February 28, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director
February 28, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
February 27, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
February 23, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
February 21, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
January 09, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
January 06, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
November 22, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the Stifel 2022 Healthcare Conference
November 09, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
November 17, 2022
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body....
Via
FinancialNewsMedia
Exposures
COVID-19
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
November 08, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
November 04, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
November 01, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
October 20, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
October 17, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
October 10, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
October 04, 2022
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Revance to Participate in the Guggenheim Nantucket Therapeutics Conference
September 21, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal
September 19, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)
September 15, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 15, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock
September 12, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces Proposed Public Offering of Common Stock
September 12, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
September 08, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Reports Second Quarter 2022 Financial Results, Provides Corporate Update
August 09, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
August 02, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference
July 27, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
May 23, 2022
From
Revance Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.